Hepatocyte Growth Factor/c-Met Invovement in Lung EC Barrier Regulation
Hepatocyte Growth Factor/c-Met Invovement in Lung EC Barrier Regulation
批准号:
7407789
负责人:
Ravi Salgia
金额:
$36.05万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-02-01 至 2013-01-31
关键词:
ActinsAcuteAcute Lung InjuryAnimal ModelArchitectureArteriosclerosisAtomic Force MicroscopyAttenuatedBindingBlood VesselsBronchoalveolar LavageCD44 AntigensCD44 geneCell Surface ReceptorsCell membraneCellsCodeCritical IllnessCytoskeletonDNA Sequence RearrangementDataDefectDiseaseDisruptionDynamin 2EdemaEndothelial CellsExtravasationGenesGlycoproteinsGrowth FactorGuanine Nucleotide Exchange FactorsHepatocyte Growth FactorHeterozygoteHumanHyaluronanImmunofluorescence ImmunologicImmunohistochemistryIn VitroInflammationInflammatoryKnockout MiceLeadLifeLipopolysaccharidesLiquid substanceLungMediatingMembrane MicrodomainsMicroscopyModelingMorbidity - disease rateMusMyosin Light Chain KinasePatientsPermeabilityPolymorphism AnalysisPredispositionProcessProductionPropertyProteinsProteomicsPublishingPulmonary EdemaReceptor Protein-Tyrosine KinasesRegulationResearchRoleSeriesSignal TransductionSignal Transduction PathwaySingle Nucleotide PolymorphismSmall Interfering RNASphingosine-1-Phosphate ReceptorStructureSystemTechniquesTestingTherapeuticTissuesTransactivationVascular PermeabilitiesVesicleX-Ray Computed Tomographyangiogenesiscaveolin 1cellular imagingcytokinedesigngenetic regulatory proteinin vivolung injurymortalitynovelpaxillinreceptorrestoration
中文摘要
点击翻译按钮获取中文摘要
英文摘要
An alteration in vascular permeability is a defining feature of diverse processes including arteriosclerosis,
inflammation, acute lung injury (ALI) and angiogenesis. In contrast, there is little known about processes that
determine barrier protection or barrier restoration after edemagenic agents. We have previously shown that
hepatocyte growth factor (HGF) binding to its cell surface receptor tyrosine kinase, c-Met, promotes increased
EC barrier function via cytoskeletal rearrangement and attenuates inflammatory lung edema formation.
Our data indicate that HGF promotes c-Met recruitment into specialized caveolin-1-enriched plasma
membrane microdomains known as lipid rafts and transactivates sphingosine 1-phosphate receptor (S1P1)
and CD44 (a major hyaluronan glycoprotein receptor) within these lipid raft structures. We have identified
several potential regulators of HGF/c-Met-induced actin cytoskeletal rearrangement and consequent EC
barrier enhancement in lipid rafts including the Rac1 exchange factor, Tiaml, the vesicle regulatory protein,
dynamin 2, myosin light chain kinase (MLCK) and paxillin. Further, genes encoding c-Met and paxillin
contain coding single nucleotide polymorphisms (SNPs) which potentially alter function and lead to increased
susceptibility to ALI. Specific Aim #1 will identify the role of these SNPs in HGF/c-Met signaling from lipid
rafts to the actin cytoskeleton and consequent human EC barrier regulation. Our preliminary data in murine
model of lipopolysaccharide (LPS)-induced pulmonary vascular hyper-permeability suggests that caveolin-1
regulates HGF-mediated vascular integrity in vivo. Specific Aim #2 will define HGF/c-Met/caveolin-1
interactions in the regulation of endothelial cortical actin formation, tension and lung permeability. Further,
our published data indicates that HGF/c-Met transactivation of the S1P1 is crucial for its EC barrierenhancing
properties. Thus, to explore growth factor transactivation in regulating EC barrier function,
Specific Aim #3 will identify HGF/c-Met/S1P1 interactions in the regulation of endothelial cortical actin
formation, tension and lung permeability. Specific Aim #4 will define HGF/c-Met/CD44 interactions in the
regulation of endothelial cortical actin formation, tension and lung permeability. Increased understanding of
HGF/c-Met-mediated signal transduction and EC barrier regulation from lipid rafts may provide novel
therapies for a variety of disease processes involving defects in EC barrier regulation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC
-
批准号:10625367
-
项目类别:
-
资助金额:$57.9万
-
财政年份:2022
-
负责人:Ravi Salgia
-
依托单位:
Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC
-
批准号:10444423
-
项目类别:
-
资助金额:$50.46万
-
财政年份:2022
-
负责人:Ravi Salgia
-
依托单位:
Hepatocyte Growth Factor/c-Met Invovement in Lung EC Barrier Regulation
-
批准号:8214992
-
项目类别:
-
资助金额:$30.06万
-
财政年份:2011
-
负责人:Ravi Salgia
-
依托单位:
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
-
批准号:7913474
-
项目类别:
-
资助金额:$9.8万
-
财政年份:2009
-
负责人:Ravi Salgia
-
依托单位:
Role of Paxillin in Lung Cancer
-
批准号:7821207
-
项目类别:
-
资助金额:$32.75万
-
财政年份:2008
-
负责人:Ravi Salgia
-
依托单位:
Role of Paxillin in Lung Cancer
-
批准号:7473452
-
项目类别:
-
资助金额:$32.68万
-
财政年份:2008
-
负责人:Ravi Salgia
-
依托单位:
Role of Paxillin in Lung Cancer
-
批准号:8255362
-
项目类别:
-
资助金额:$31.85万
-
财政年份:2008
-
负责人:Ravi Salgia
-
依托单位:
Role of Paxillin in Lung Cancer
-
批准号:7908470
-
项目类别:
-
资助金额:$18.68万
-
财政年份:2008
-
负责人:Ravi Salgia
-
依托单位:
Role of Paxillin in Lung Cancer
-
批准号:8064353
-
项目类别:
-
资助金额:$31.81万
-
财政年份:2008
-
负责人:Ravi Salgia
-
依托单位:
Role of Paxillin in Lung Cancer
-
批准号:7629794
-
项目类别:
-
资助金额:$32.72万
-
财政年份:2008
-
负责人:Ravi Salgia
-
依托单位:
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
-
批准号:7340780
-
项目类别:
-
资助金额:$26.25万
-
财政年份:2007
-
负责人:Ravi Salgia
-
依托单位:
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
-
批准号:7995258
-
项目类别:
-
资助金额:$25.46万
-
财政年份:2007
-
负责人:Ravi Salgia
-
依托单位:
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
-
批准号:7742242
-
项目类别:
-
资助金额:$26.25万
-
财政年份:2007
-
负责人:Ravi Salgia
-
依托单位:
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
-
批准号:7190133
-
项目类别:
-
资助金额:$26.25万
-
财政年份:2007
-
负责人:Ravi Salgia
-
依托单位:
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
-
批准号:7535611
-
项目类别:
-
资助金额:$26.25万
-
财政年份:2007
-
负责人:Ravi Salgia
-
依托单位:
Role of c-Met in SCLC and Potential for Novel Therapy
-
批准号:7014510
-
项目类别:
-
资助金额:$24.42万
-
财政年份:2004
-
负责人:Ravi Salgia
-
依托单位:
Role of c-Met in SCLC and Potential for Novel Therapy
-
批准号:8225278
-
项目类别:
-
资助金额:$24.11万
-
财政年份:2004
-
负责人:Ravi Salgia
-
依托单位:
Role of c-Met in SCLC and Potential for Novel Therapy
-
批准号:6858691
-
项目类别:
-
资助金额:$25.01万
-
财政年份:2004
-
负责人:Ravi Salgia
-
依托单位:
Role of c-Met in SCLC and Potential for Novel Therapy
-
批准号:6731788
-
项目类别:
-
资助金额:$25.01万
-
财政年份:2004
-
负责人:Ravi Salgia
-
依托单位:
Role of c-Met in SCLC and Potential for Novel Therapy
-
批准号:7185110
-
项目类别:
-
资助金额:$23.71万
-
财政年份:2004
-
负责人:Ravi Salgia
-
依托单位:
海外基金